ScholarLens Back to search
2023•Unpublished venueOpen access

Supplementary Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma

Cara Haymaker, Daniel Hartman Johnson, RAVI K. MURTHY, Salah-Eddine Bentebibel, Marc Isamu Uemura, Courtney W. Hudgens, Houssein Safa, Marihella L. James, Robert H.I. Andtbacka, Douglas B. Johnson, Montaser F. Shaheen, Michael A. Davies, Shah Rahimian, Srinivas K. Chunduru, Denái R. Milton, Michael T. Tetzlaff, Willem W. Overwijk, Patrick Hwu, Nashat Y. Gabrail, Sudhir Agrawal, Gary C. Doolittle, Igor J. Puzanov, Joseph Markowitz, Chantale Bernatchez, Adi Diab

Open full text 0 citations

Abstract

Supplementary Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma

About this research paper

What this paper is about

Supplementary Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Supplementary Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma

Key concepts: Ipilimumab, Refractory (planetary science), Melanoma, Medicine, Oncology, Internal medicine, Cancer research, Immunotherapy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Supplementary Data from Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma — Research Paper | ScholarLens